NO20064547L - Fremgangsmater for behandling av HIV infeksjon - Google Patents

Fremgangsmater for behandling av HIV infeksjon

Info

Publication number
NO20064547L
NO20064547L NO20064547A NO20064547A NO20064547L NO 20064547 L NO20064547 L NO 20064547L NO 20064547 A NO20064547 A NO 20064547A NO 20064547 A NO20064547 A NO 20064547A NO 20064547 L NO20064547 L NO 20064547L
Authority
NO
Norway
Prior art keywords
methods
hiv infection
treating hiv
treating
aids
Prior art date
Application number
NO20064547A
Other languages
English (en)
Other versions
NO337116B1 (no
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064547(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20064547L publication Critical patent/NO20064547L/no
Publication of NO337116B1 publication Critical patent/NO337116B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen omfatter farmasøytiske sammensetninger og fremgangsmåter for anvendelse av forbindelse I i kombinasjon med andre midler for behandling av pasienter med AIDS eller HIV-infeksjon.
NO20064547A 2004-03-24 2006-10-06 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioksoetyl]-piperazin eller et farmasøytisk akseptabelt salt derav, og minst et annet middel, anvendt for behandling av AIDS eller HIV-infeksjon samt farmasøytisk preparat omfattende samme NO337116B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (2)

Publication Number Publication Date
NO20064547L true NO20064547L (no) 2006-10-06
NO337116B1 NO337116B1 (no) 2016-01-25

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064547A NO337116B1 (no) 2004-03-24 2006-10-06 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioksoetyl]-piperazin eller et farmasøytisk akseptabelt salt derav, og minst et annet middel, anvendt for behandling av AIDS eller HIV-infeksjon samt farmasøytisk preparat omfattende samme

Country Status (31)

Country Link
US (1) US7776863B2 (no)
EP (1) EP1732604B1 (no)
JP (1) JP4847441B2 (no)
KR (1) KR101158140B1 (no)
CN (1) CN1956720B (no)
AR (1) AR048333A1 (no)
AT (1) ATE474602T1 (no)
AU (1) AU2005235116B2 (no)
BR (1) BRPI0509140A (no)
CA (1) CA2561146C (no)
CY (1) CY1111613T1 (no)
DE (1) DE602005022420D1 (no)
DK (1) DK1732604T3 (no)
ES (1) ES2347801T3 (no)
GE (1) GEP20104925B (no)
HK (1) HK1096540A1 (no)
HR (1) HRP20100434T1 (no)
IL (1) IL178141A (no)
IN (1) IN2012DN06436A (no)
MY (1) MY144318A (no)
NO (1) NO337116B1 (no)
NZ (1) NZ549778A (no)
PE (1) PE20060148A1 (no)
PL (1) PL1732604T3 (no)
PT (1) PT1732604E (no)
RU (1) RU2367439C2 (no)
SI (1) SI1732604T1 (no)
TW (1) TWI347184B (no)
UA (1) UA88463C2 (no)
WO (1) WO2005102392A2 (no)
ZA (1) ZA200607959B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
CN102076686B (zh) * 2008-06-25 2013-03-06 百时美施贵宝公司 作为hiv附着抑制剂的二酮哌啶衍生物
CN102131810B (zh) 2008-06-25 2014-02-26 百时美施贵宝公司 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
US8450361B2 (en) 2010-08-06 2013-05-28 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
DK2670751T3 (en) 2011-01-31 2015-07-20 Bristol Myers Squibb Co PROCEDURES FOR MANUFACTURING HIV BINDING INHIBITOR PRODUCT CONNECTION AND INTERMEDIATES
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
EP2751118B1 (en) 2011-08-29 2016-10-12 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
WO2014160692A1 (en) * 2013-03-27 2014-10-02 Bristol-Myers Squibb Company 2-keto amide derivatives as hiv attachment inhibitors
CA2988650A1 (en) 2015-06-23 2016-12-29 Cytodyn Inc. Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ506623A (en) * 1998-03-02 2002-10-25 Univ North Carolina Acylated betulin and dihydrobetulin derivatives, preparation thereof and use in treatment of retroviral infections
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL370664A1 (en) * 2001-12-12 2005-05-30 Bristol-Myers Squibb Company Hiv integrase inhibitors
MXPA04006136A (es) * 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.

Also Published As

Publication number Publication date
JP2007530540A (ja) 2007-11-01
AU2005235116A1 (en) 2005-11-03
IL178141A0 (en) 2006-12-31
TWI347184B (en) 2011-08-21
WO2005102392A3 (en) 2006-07-20
EP1732604B1 (en) 2010-07-21
GEP20104925B (en) 2010-03-25
SI1732604T1 (sl) 2010-10-29
DE602005022420D1 (de) 2010-09-02
HRP20100434T1 (hr) 2010-09-30
KR101158140B1 (ko) 2012-06-19
PE20060148A1 (es) 2006-03-04
PT1732604E (pt) 2010-09-24
MY144318A (en) 2011-08-29
CN1956720B (zh) 2010-12-15
CA2561146C (en) 2013-12-24
ES2347801T3 (es) 2010-11-04
JP4847441B2 (ja) 2011-12-28
US20050215545A1 (en) 2005-09-29
CN1956720A (zh) 2007-05-02
NO337116B1 (no) 2016-01-25
CY1111613T1 (el) 2015-10-07
HK1096540A1 (en) 2007-06-01
BRPI0509140A (pt) 2007-09-04
RU2006137555A (ru) 2008-04-27
WO2005102392A2 (en) 2005-11-03
IN2012DN06436A (no) 2015-10-09
NZ549778A (en) 2010-09-30
UA88463C2 (ru) 2009-10-26
IL178141A (en) 2010-11-30
CA2561146A1 (en) 2005-11-03
ATE474602T1 (de) 2010-08-15
US7776863B2 (en) 2010-08-17
AU2005235116B2 (en) 2011-03-31
TW200538117A (en) 2005-12-01
AR048333A1 (es) 2006-04-19
DK1732604T3 (da) 2010-11-15
PL1732604T3 (pl) 2010-12-31
ZA200607959B (en) 2008-06-25
EP1732604A2 (en) 2006-12-20
KR20070011322A (ko) 2007-01-24
RU2367439C2 (ru) 2009-09-20

Similar Documents

Publication Publication Date Title
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
WO2006034001A3 (en) Methods of treating hiv infection
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
NO20070988L (no) Vaksine for forebygging og behandling av HIV-infeksjon
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
DK1458360T3 (da) Pulmonær afgivelse af aminoglycosider
MX2010002319A (es) Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
EP1753777A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING HIV INFECTION WITH TRIM5a
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
ATE414092T1 (de) Phosphoindole als hiv-inhibitoren
TW200738700A (en) HIV integrase inhibitors
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
CR20230164A (es) Compuestos fosfolípidos y usos de estos
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20071706L (no) Koadministrering av Tigecycline og Digoxin.
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
WO2007081365A3 (en) Multiple antigenic agents and methods for using the same
RU2007145646A (ru) Средство для лечения вич-инфекции
UA110918C2 (uk) Інгібітори протеїнфосфатази-1 та їх застосування

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: VIIV HEALTHCARE UK (NO. 5) LIMITED, GB